New Biosimilar Approval Pathway Creates Device Opportunities
This article was originally published in The Gray Sheet
Executive Summary
A new abbreviated regulatory pathway established by Congress for the approval of off-patent recombinant protein therapeutics could open up U.S. market opportunities for injection device technology firms